Drugs / Bocidelpar
Bocidelpar
also known as
ASP0367 · ASP0367 hemisulfate · BOCIDELPAR SULFATE · MA-0211 · MA-0211 HEMISULFATE · MTB-1
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05217901 | Jan → Apr 2022 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05117294 | Dec 2021 → Nov 2022 | impaired renal function disease | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04942964 | Sep 2021 → Jan 2022 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04855201 | Jun 2021 → Dec 2022 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04184882 | Feb 2021 → Sep 2022 | Duchenne muscular dystrophy | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 1 | NCT03682484 | Jun 2017 → Mar 2018 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04641962 | May 2021 → May 2024 | pure mitochondrial myopathy | Astellas Pharma Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-20 | Astellas Pharma Inc | Regulatory U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator Being Developed for the Treatment of Primary Mitochondrial Myopathies astellas.com ↗
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP0367/MA-0211 (“ASP0367”) as a potential treatment for primary mitochondrial myopathies (PMM). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-20 | Astellas Pharma Inc | U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator Being Developed for the Treatment of Primary Mitochondrial Myopathies astellas.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bocidelpar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04641962 ↗ |
| Known as | ASP0367 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05217901 ↗ |
| Known as | ASP0367 hemisulfate | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095171 ↗ |
| Known as | BOCIDELPAR SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095171 ↗ |
| Known as | MA-0211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682484 ↗ |
| Known as | MA-0211 HEMISULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095171 ↗ |
| Known as | MTB-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095171 ↗ |
| Modality | Small molecule | — CHEMBL5095171 ↗ |
| Route | Oral | “oral doses of MA-0211 or matching Placebo for 14 days.” NCT03682484 ↗ |